Gonadotropin-Releasing Hormone (GnRH) Agonists & Antagonists Drugs Market Report 2025: Trends, Drivers & Forecasts

The Business Research Company

The Business Research Company's Gonadotropin-Releasing Hormone (GnRH) Agonists & Antagonists Drugs Market Report 2025 – Market Size And Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, August 21, 2025 /EINPresswire.com/ -- "Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Growth Forecast: What To Expect By 2025?
The market size of drugs including gonadotropin-releasing hormone (GnRH) agonists and antagonists has seen substantial growth recently. The market is projected to expand from $1.57 billion in 2024 to $1.73 billion in 2025, experiencing a compound annual growth rate (CAGR) of 9.8%. Factors contributing to this historical growth include the rising incident rates of hormone-related disorders and breast and prostate cancer, higher awareness regarding reproductive health, an increased call for assisted reproductive technologies, and a growing trend of utilizing hormone therapies for conditions such as endometriosis and uterine fibroids.

The market for gonadotropin-releasing hormone (GnRH) agonists and antagonists medication is expected to witness a sizable increase in the coming years, with a surge to $2.49 billion predicted by 2029 at a compound annual growth rate (CAGR) of 9.5%. Several factors are contributing to this growth over the forecast period, including the growing preference for less invasive treatments, increased awareness of women's health issues, a rise in the availability of combination therapies, enhanced healthcare access in emerging regions, and a burgeoning pipeline of innovative formulations. Future trends that will impact the forecasted period include progress in oral GnRH antagonist formulations, the development of combination therapies with hormonal add-back, the incorporation of digital healthcare instruments in monitoring reproductive treatments, advancements in clinical trial designs to expedite approvals, and the introduction of telemedicine in hormone therapy.

Download a free sample of the gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25772&type=smp

What Are The Major Driving Forces Influencing The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Landscape?
The growth of the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market is predicted to be driven by the rising occurrence of ovarian and prostate cancers. These hormone-sensitive tumours are impacted by estrogen and testosterone and are frequently treated with hormone-modulating therapies like GnRH agonists or antagonists. The escalation in ovarian and prostate cancers can be attributed to increased life expectancy, as the probability of developing these hormone-sensitive cancers augments with age. GnRH agonists and antagonists aid in the treatment of ovarian and prostate cancers by inhibiting the production of sex hormones such as estrogen and testosterone which stimulate the proliferation of these hormone-sensitive tumours. For instance, Cancer Australia, a government agency in Australia, estimated about 1,786 new ovarian cancer cases to be diagnosed in the year 2023. Furthermore, there is about a 1.2% risk (or 1 in 87 chance) of women being diagnosed with ovarian cancer by the time they reach 85. Consequently, the enlarging incidence of ovarian and prostate cancers is fueling the expansion of the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market.

Who Are The Leading Players In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market?
Major players in the Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Global Market Report 2025 include:
• Pfizer Inc.
• AbbVie Inc.
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Intas Pharmaceuticals Limited
• Sumitomo Pharma Co. Ltd.
• Ipsen S.A.
• Dr. Reddy's Laboratories Limited
• Cipla Limited.

What Are Some Emerging Trends In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market?
Leading firms in the GnRH agonists and antagonists drugs sector are targeting the development of advanced solutions like oral GnRH receptor antagonists. Their goal is to enhance the ease of patients, improve adherence to treatment, and decrease dependence on injectable therapies. An oral GnRH receptor antagonist is a pill that offers quick reduction in sex hormone levels by blocking GnRH receptors, making it beneficial for treating hormone-related conditions like prostate cancer and endometriosis. For example, in March 2024, Sumitomo Pharma Co. Ltd., a pharmaceutical organization based in Japan, revealed that Health Canada had approved for use in Canada its ORGOVYX (relugolix), the first-ever oral androgen deprivation therapy (ADT) for advanced prostate cancer. Taken once a day, ORGOVYX, an oral GnRH receptor antagonist, suppresses the production of testosterone, a primary contributor to the advancement of prostate cancer. The approval was contingent on the results of the Phase 3 HERO study, which showed effective and prolonged suppression of testosterone, a decrease in significant cardiovascular events, and castration resistance-free survival on par with standard injectable therapies.

Analysis Of Major Segments Driving The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Growth
The gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market covered in this report is segmented –
1) By Drug Type: GnRH Agonists, Leuprorelin, Goserelin, Triptorelin, Histrelin, Buserelin, GnRH Antagonists, Degarelix, Abarelix, Other Drug Types
2) By Application: Gynecology, Oncology, Other Applications
3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:
1) By GnRH Agonists: Deslorelin, Gonadorelin, Zoladex Long-Acting Goserelin Variant, Lupron Depot-Ped, Sustained-Release Microsphere Formulations
2) By Leuprorelin: Depot Injection, Implant, Combination Therapy Formulations
3) By Goserelin: Subcutaneous Implant, Oncology-Specific Formulation, Gynecology-Specific Formulation
4) By Triptorelin: Intramuscular Injection, Long-Acting (1-, 3-, 6-Month) Depot, Fertility Treatment Formulation
5) By Histrelin: Subcutaneous Implant, Pediatric (Precocious Puberty) Formulation, Adult Prostate Cancer-Specific Version
6) By Buserelin: Nasal Spray, Subcutaneous Injection, In Vitro Fertilization And Fertility Cycle Formulations
7) By GnRH Antagonists: Teverelix DP, Elagolix, Relugolix, Ganirelix, Linzagolix
8) By Degarelix: Subcutaneous Injection, Monthly Dosing, Prostate Cancer-Specific Formulation
9) By Abarelix: Intramuscular Injection, Advanced Prostate Cancer, Short-Acting Formulation
10) By Other Drug Types: Subcutaneous Injection, In Vitro Fertilization-Specific Use, Multiple Dosing Regimens

View the full gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market report:
https://www.thebusinessresearchcompany.com/report/gonadotropin-releasing-hormone-gnrh-agonists-and-antagonists-drugs-global-market-report

Which Region Is Expected To Lead The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market By 2025?
For the year specified in the Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Global Market Report 2025, North America dominated as the largest region. It's anticipated that Asia-Pacific will witness the most rapid growth in the forecast period. The report features an extensive regional analysis covering Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market 2025, By The Business Research Company

Gonadotropin Releasing Hormone Gnrh Agonist Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gonadotropin-releasing-hormone-gnrh-agonist-global-market-report

Gynecology Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gynecology-drugs-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.